Kymera Therapeutics, Inc.
NASDAQ:KYMR
35.1 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 47.072 | 78.592 | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
| Cost of Revenue
| 0 | 189.081 | 2.977 | 2.397 | 62.105 | 0.825 | 0.205 |
| Gross Profit
| 47.072 | -110.489 | 43.849 | 70.435 | -28.071 | 2.109 | -0.205 |
| Gross Profit Ratio
| 1 | -1.406 | 0.936 | 0.967 | -0.825 | 0.719 | 0 |
| Reseach & Development Expenses
| 240.248 | 189.081 | 164.248 | 137.017 | 62.105 | 37.158 | 17.679 |
| General & Administrative Expenses
| 63.534 | 55.041 | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 63.534 | 55.041 | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
| Other Expenses
| 4.925 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 308.707 | 244.122 | 208.082 | 173.362 | 80.338 | 45.139 | 21.451 |
| Operating Income
| -261.635 | -165.53 | -161.256 | -100.53 | -46.304 | -42.205 | -21.451 |
| Operating Income Ratio
| -5.558 | -2.106 | -3.444 | -1.38 | -1.361 | -14.385 | 0 |
| Total Other Income Expenses Net
| 37.777 | 18.568 | 6.448 | 0.313 | 0.711 | 0.959 | -0.016 |
| Income Before Tax
| -223.858 | -146.962 | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
| Income Before Tax Ratio
| -4.756 | -1.87 | -3.306 | -1.376 | -1.34 | -14.058 | 0 |
| Income Tax Expense
| 0 | 0 | -2.977 | -2.222 | -1.648 | 0.046 | 0.044 |
| Net Income
| -223.858 | -146.962 | -151.831 | -97.995 | -43.945 | -41.292 | -21.467 |
| Net Income Ratio
| -4.756 | -1.87 | -3.242 | -1.345 | -1.291 | -14.074 | 0 |
| EPS
| -2.98 | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted
| -2.98 | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EBITDA
| -216.236 | -143.201 | -151.655 | -97.645 | -43.715 | -40.375 | -21.246 |
| EBITDA Ratio
| -4.594 | -1.822 | -3.302 | -1.374 | -1.336 | -13.761 | 0 |